Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

NCT01243359 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

NIH

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Cancer
Stage I Renal Cell Cancer
Stage II Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: sunitinib malate
BIOLOGICAL: bevacizumab
OTHER: pharmacological study
OTHER: laboratory biomarker analysis
OTHER: fluorine F 18 fluorothymidine
PROCEDURE: positron emission tomography
PROCEDURE: computed tomography

Sponsor

National Cancer Institute (NCI)